Development of metastatic HER2+ breast cancer is independent of the adaptive immune system

Journal of Pathology

Volumn 224, Issue 1, 2011, Pages 56-66

  Ciampricotti, Metamia ^a   Vrijland, Kim ^a   Hau, Cheei Sing ^a   Pemovska, Tea ^a   Doornebal, Chris W ^a   Speksnijder, Ewoud N ^c   Wartha, Katharina ^b   Jonkers, Jos ^a   De Visser, Karin E ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

adaptive immune system; breast cancer; Her2 neu; immunosurveillance; innate immune system; metastasis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BREAST CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE;

ADAPTIVE IMMUNITY; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC SURVEILLANCE; LUNG NEOPLASMS; LYMPHOCYTE SUBSETS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; RECEPTOR, ERBB-2; TUMOR MICROENVIRONMENT;

EID: 79953801387     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2837     Document Type: Article

References (51)

1. Dunn GP, Old LJ, Schreiber RD,. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-148. (Pubitemid 39094044)
2. Willimsky G, Blankenstein T,. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005; 437: 141-146. (Pubitemid 41613441)
3. de Visser KE, Eichten A, Coussens LM,. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6: 24-37. (Pubitemid 43053650)
4. Pardoll DM,. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003; 21: 807-839.
5. Shankaran V, Ikeda H, Bruce AT, et al., IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-1111. (Pubitemid 32391043)
6. Dunn GP, Bruce AT, Ikeda H, et al., Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-998. (Pubitemid 35363648)
7. Casanovas O, Hicklin DJ, Bergers G, et al., Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309. (Pubitemid 41443415)
8. de Visser KE, Korets LV, Coussens LM,. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005; 7: 411-423. (Pubitemid 40719125)
9. Haybaeck J, Zeller N, Wolf MJ, et al., A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009; 16: 295-308.
10. + T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16: 91-102.
11. Andreu P, Johansson M, Affara NI, et al., FcRγ activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 2010; 17: 121-134.
12. Perou CM, Sorlie T, Eisen MB, et al., Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
13. Linn SC, Van 't Veer LJ,. Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. Eur J Cancer 2009; 45 (suppl 1): 11-26.
14. Burstein HJ,. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005; 353: 1652-1654. (Pubitemid 41464703)
15. Desmedt C, Haibe-Kains B, Wirapati P, et al., Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008; 14: 5158-5165.
16. Slamon DJ, Godolphin W, Jones LA, et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712. (Pubitemid 19147683)
17. + breast cancers correlates with lower recurrence rates. Cancer Res 2007; 67: 10669-10676. (Pubitemid 350145892)
18. Rody A, Holtrich U, Pusztai L, et al., T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 2009; 11: R15.
19. Stewart T, Tsai SC, Grayson H, et al., Incidence of de novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 1995; 346: 796-798.
20. Engels EA, Goedert JJ,. Human immunodeficiency virus/acquired immunodeficiency syndrome and cancer: past, present, and future. J Natl Cancer Inst 2005; 97: 407-409. (Pubitemid 40528595)
21. Muller WJ, Sinn E, Pattengale PK, et al., Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988; 54: 105-115.
22. Boggio K, Nicoletti G, Di Carlo E, et al., Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 1998; 188: 589-596. (Pubitemid 28369147)
23. Shinkai Y, Rathbun G, Lam KP, et al., RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992; 68: 855-867.
24. Weijer K, Uittenbogaart CH, Voordouw A, et al., Intrathymic and extrathymic development of human plasmacytoid dendritic cell precursors in vivo. Blood 2002; 99: 2752-2759. (Pubitemid 34525362)
25. Evers B, Speksnijder EN, Schut E, et al., A tissue reconstitution model to study cancer cell-intrinsic and -extrinsic factors in mammary tumourigenesis. J Pathol 2010; 220: 34-44.
26. Hoebe K, Janssen E, Beutler B,. The interface between innate and adaptive immunity. Nat Immunol 2004; 5: 971-974. (Pubitemid 41057712)
27. Shanker A,. Adaptive control of innate immunity. Immunol Lett 2010; (in press).
28. Seruga B, Zhang H, Bernstein LJ, et al., Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 2008; 8: 887-899.
29. Balkwill F,. Tumour necrosis factor and cancer. Nat Rev Cancer 2009; 9: 361-371.
30. de Visser KE,. Spontaneous immune responses to sporadic tumors: tumor-promoting, tumor-protective or both? Cancer Immunol Immunother 2008; 57: 1531-1539.
31. Takeuchi N, Hiraoka S, Zhou XY, et al., Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice. Cancer Res 2004; 64: 7588-7595. (Pubitemid 39372104)
32. Kmieciak M, Morales JK, Morales J, et al., Danger signals and non-self entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design. Cancer Immunol Immunother 2008; 57: 1391-1398.
33. Disis ML, Calenoff E, McLaughlin G, et al., Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994; 54: 16-20. (Pubitemid 24042079)
34. Peoples GE, Goedegebuure PS, Smith R, et al., Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995; 92: 432-436.
35. Park JM, Terabe M, Donaldson DD, et al., Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation. Cancer Immunol Immunother 2008; 57: 907-912.
36. Melani C, Chiodoni C, Forni G, et al., Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003; 102: 2138-2145. (Pubitemid 37122391)
37. Ambrosino E, Spadaro M, Iezzi M, et al., Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res 2006; 66: 7734-7740. (Pubitemid 44289233)
38. + T cell function via L -arginine metabolism. Cancer Res 2009; 69: 3086-3094.
39. Rovero S, Amici A, Carlo ED, et al., DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000; 165: 5133-5142.
40. Spadaro M, Lanzardo S, Curcio C, et al., Immunological inhibition of carcinogenesis. Cancer Immunol Immunother 2004; 53: 204-216. (Pubitemid 38328043)
41. Rolla S, Ria F, Occhipinti S, et al., Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy. J Immunol 2010; 184: 6124-6132.
42. Park S, Jiang Z, Mortenson ED, et al., The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18: 160-170.
43. Shchors K, Shchors E, Rostker F, et al., The Myc-dependent angiogenic switch in tumors is mediated by interleukin-1β. Genes Dev 2006; 20: 2527-2538. (Pubitemid 44396838)
44. Soucek L, Lawlor ER, Soto D, et al., Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007; 13: 1211-1218. (Pubitemid 47530639)
45. Sparmann A, Bar-Sagi D,. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004; 6: 447-458. (Pubitemid 39469981)
46. Yarden Y, Sliwkowski MX,. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137. (Pubitemid 33674041)
47. Casares N, Pequignot MO, Tesniere A, et al., Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202: 1691-1701. (Pubitemid 41815875)
48. Apetoh L, Ghiringhelli F, Tesniere A, et al., Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059. (Pubitemid 47517504)
49. Herschkowitz JI, Simin K, Weigman VJ, et al., Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007; 8: R76.
50. Derksen PW, Liu X, Saridin F, et al., Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006; 10: 437-449. (Pubitemid 44693469)
51. Frese KK, Tuveson DA,. Maximizing mouse cancer models. Nat Rev Cancer 2007; 7: 645-658. (Pubitemid 47327410)